Test Price
2,800 AED✅ Home Collection Available
GLB1 Gene GM1-Gangliosidosis Type 2 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين GLB1 لداء الغانغليوزيد GM1 النوع الثاني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي: اختبار تسلسل الجينوم من الجيل التالي (NGS) لجين GLB1 للكشف عن داء الغانغليوزيد GM1 النوع الثاني — اضطراب استقلابي وراثي نادر. حساسية تشخيصية بنسبة 99.9% عبر مختبر حاصل على شهادة الآيزو. يشمل السعر خدمة سحب دم منزلي بطاقم تمريض متنقل مع سلسلة تبريد معتمدة، واستشارة طبية هاتفية بعد الفحص لتفسير النتائج، والتحقق المباشر من التغطية التأمينية.
- دقة الضمان: حساسية تشخيصية 99.9% عبر معالجة معتمدة بموجب ISO 9001:2015.
- الخدمات اللوجستية المتميزة: سحب دم منزلي على درجة المستشفى عبر سلسلة تبريد معتمدة وفريق تمريض متنقل VIP.
- الإرشاد السريري: استشارة طبية هاتفية بعد الفحص لتفسير النتائج سريرياً.
- التأمين: التحقق المباشر من التغطية التأمينية عبر واتساب: +971 54 548 8731
Clinical Overview — GLB1 Gene & GM1-Gangliosidosis Type 2
The GLB1 Gene GM1-Gangliosidosis Type 2 Genetic Test utilizes Genetic Test is essential for confirming a clinical suspicion, guiding management, and enabling informed family planning. يكشف هذا الاختبار الطفرات الجينية المسببة لنقص إنزيم بيتا غالاكتوزيداز.
A pre-test genetic counselling session is required to construct a detailed pedigree chart of family members affected with GM1-gangliosidosis type 2, ensuring appropriate clinical context and informed consent are established prior to sample collection.
| Parameter | Our Test — GLB1 NGS (UAE) | Closest Alternative — Biochemical Enzyme Assay |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity — Full gene coverage including deep intronic regions | ~85% Sensitivity — Limited to enzymatic activity; may miss heterozygotes |
| Methodology | NGS (Next Generation Sequencing) with CNV analysis | Fluorometric enzyme assay on leukocytes or fibroblasts |
| Turnaround Time | 3 to 4 Weeks | 2 to 6 Weeks (often requires specialized referral lab) |
| Clinical Utility | Definitive genotypic diagnosis; carrier testing; prenatal applicability | Phenotypic confirmation only; no variant-level data |
Physician Insight & Safety Protocol
Clinical Note from Dr. Prabhakar Reddy (DHA License: 61713011):
"This NGS-based GLB1 gene test is a powerful diagnostic tool, yet it must be interpreted within the full clinical picture — neurodevelopmental regression, coarse facial features, and skeletal abnormalities are cardinal signs. A negative result does not entirely exclude the diagnosis if clinical suspicion remains high, and I strongly advise that all results be correlated with biochemical enzyme testing and neurological assessment before any irreversible clinical decision is made."
Medication Warning
Do not discontinue any prescribed medication, including anticonvulsants, muscle relaxants, or nutritional support regimens, without consulting your treating physician. Genetic test results provide diagnostic clarity but do not constitute a pharmacological directive. Abrupt medication changes in metabolic disorders may precipitate acute decompensation.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed With Test If):
- Patient is a minor and legal guardian consent cannot be verified (per UAE CDS Law 2026, Art. 12)
- Inadequate sample integrity — hemolyzed or clotted whole blood specimen
- Incomplete pre-test genetic counselling and unsigned informed consent documentation
- Recent blood transfusion (< 2 weeks) potentially confounding germline DNA analysis
Emergency Red Flags — Seek Immediate Medical Attention If:
- Progressive loss of motor milestones or sudden onset of seizures
- Acute respiratory distress or aspiration events
- Unexplained lethargy, hypotonia, or failure to thrive in a pediatric patient
- Signs of increased intracranial pressure (vomiting, irritability, sunsetting eyes)
Specimen Requirements, Turnaround & Collection Logistics
Accepted Sample Types
- Whole Blood (EDTA tube, 3-5 mL)
- Extracted DNA (minimum 2 μg, A260/A280 ratio 1.8-2.0)
- One Drop Blood on FTA Card (properly dried, labelled)
Turnaround Time
3 to 4 Weeks from sample receipt at laboratory. Expedited reporting available upon request for urgent clinical scenarios.
Home Collection Service
VIP Mobile Phlebotomy available 8 AM – 11 PM, 7 days a week. ISO-certified cold-chain transport. Book via WhatsApp: +971 54 548 8731
Pre-Test Requirement: A genetic counselling session to draw a pedigree chart of family members affected with GM1-gangliosidosis type 2 is mandatory. This ensures clinically contextualized reporting and facilitates accurate variant interpretation. جلسة استشارة وراثية إلزامية قبل الفحص لرسم شجرة العائلة.
Patient FAQ & Clinical Guidance
1. What does the GLB1 gene NGS test diagnose, and who should consider it?
This test definitively identifies pathogenic variants in the GLB1 gene causing GM1-gangliosidosis type 2, a juvenile-onset lysosomal storage disorder characterized by progressive neurodegeneration, skeletal dysplasia, and coarse facial features. Individuals with unexplained neurodevelopmental regression, a family history of metabolic disorders, or those seeking carrier status clarification should consider this test following genetic counselling.
2. How reliable is NGS technology compared to traditional enzyme testing for GM1-gangliosidosis?
NGS delivers 99.9% diagnostic sensitivity by sequencing the entire GLB1 gene, detecting point mutations, small insertions or deletions, and copy number variations that biochemical enzyme assays cannot resolve. While enzyme testing quantifies beta-galactosidase activity, NGS provides the definitive genotypic confirmation necessary for accurate prognosis, family screening, and reproductive planning.
3. هل اختبار GLB1 الجيني يغطيه التأمين الصحي في الإمارات؟ Is the GLB1 genetic covered by UAE health insurance?
Insurance coverage for genetic testing in the UAE depends on your policy's specific provisions for molecular diagnostics and hereditary disorder screening. We provide direct billing verification via WhatsApp at +971 54 548 8731 — simply share your insurance card, and our team confirms coverage status before sample collection. نوفر التحقق المباشر من التغطية التأمينية عبر واتساب قبل إجراء الفحص.
UAE Regulatory Compliance
- Federal Decree-Law No. 41 of 2024 (Art. 87) — Healthcare Data Confidentiality
- CDS Law 2026 — Minors' Consent & Genetic Testing Provisions
- UAE PDPL — Personal Data Protection Law Compliance
- DHA Facility License: 9834453
International Accreditation
- ISO 9001:2015 — Quality Management Systems
- Certification: INT/EGQ/2509DA/3139
- NGS Methodology validated per CAP/CLIA-equivalent standards
- LOINC: 101655-8 — GLB1 gene mutations in Blood by NGS
2026 ICD-10-CM Codes (Top 3): E75.19 — GM1 Gangliosidosis (Type 2, Juvenile-Onset) | Z14.8 — Genetic Carrier Status for Other Genetic Diseases | Z13.79 — Encounter for Screening for Other Genetic and Chromosomal Anomalies
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians